14 research outputs found
Far infrared polarimeter with very low instrumental polarization
After a short analysis of the main problems involved in the construction of a
Far Infrared polarimeter with very low instrumental noise, we describe the
instrument that will be employed at MITO telescope to search for calibration
sources and investigate polarization near the CMB anisotropy peaks in the next
campaign (Winter 2002-03).Comment: 9 pages, 5 figures, to appear in SPIE conference proceedings
"Astronomical telescopes and instrumentation
MITO measurements of the Sunyaev-Zeldovich Effect in the Coma cluster of galaxies
We have measured the Sunyaev-Zeldovich effect towards the Coma cluster
(A1656) with the MITO experiment, a 2.6-m telescope equipped with a 4-channel
17 arcminute (FWHM) photometer. Measurements at frequency bands 143+/-15,
214+/-15, 272+/-16 and 353+/-13 GHz, were made during 120 drift scans of Coma.
We describe the observations and data analysis that involved extraction of the
S-Z signal by employing a spatial and spectral de-correlation scheme to remove
a dominant atmospheric component. The deduced values of the thermal S-Z effect
in the first three bands are DT_{0} = -179+/-38,-33+/-81,170+/-35 microKelvin
in the cluster center. The corresponding optical depth, tau=(4.1+/-0.9)
10^{-3}, is consistent (within errors) with both the value from a previous low
frequency S-Z measurement, and the value predicted from the X-ray deduced gas
parameters.Comment: Ap.J.Letters accepted, 4 pages, 2 figure
Noncoding rnas and midbrain da neurons: Novel molecular mechanisms and therapeutic targets in health and disease
Midbrain dopamine neurons have crucial functions in motor and emotional control and their degeneration leads to several neurological dysfunctions such as Parkinson’s disease, addiction, depression, schizophrenia, and others. Despite advances in the understanding of specific altered proteins and coding genes, little is known about cumulative changes in the transcriptional landscape of noncoding genes in midbrain dopamine neurons. Noncoding RNAs—specifically microRNAs and long noncoding RNAs—are emerging as crucial post-transcriptional regulators of gene expression in the brain. The identification of noncoding RNA networks underlying all stages of dopamine neuron development and plasticity is an essential step to deeply understand their physiological role and also their involvement in the etiology of dopaminergic diseases. Here, we provide an update about noncoding RNAs involved in dopaminergic development and metabolism, and the related evidence of these biomolecules for applications in potential treatments for dopaminergic neurodegeneration
Noncoding rnas and midbrain da neurons: Novel molecular mechanisms and therapeutic targets in health and disease
Midbrain dopamine neurons have crucial functions in motor and emotional control and their degeneration leads to several neurological dysfunctions such as Parkinson’s disease, addiction, depression, schizophrenia, and others. Despite advances in the understanding of specific altered proteins and coding genes, little is known about cumulative changes in the transcriptional landscape of noncoding genes in midbrain dopamine neurons. Noncoding RNAs—specifically microRNAs and long noncoding RNAs—are emerging as crucial post-transcriptional regulators of gene expression in the brain. The identification of noncoding RNA networks underlying all stages of dopamine neuron development and plasticity is an essential step to deeply understand their physiological role and also their involvement in the etiology of dopaminergic diseases. Here, we provide an update about noncoding RNAs involved in dopaminergic development and metabolism, and the related evidence of these biomolecules for applications in potential treatments for dopaminergic neurodegeneration
Thermodynamics, size, and dynamics of zwitterionic dodecylphosphocholine and anionic sodium dodecyl sulfate mixed micelles
Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention
Background: People who inject drugs (PWID) are a key population affected
by hepatitis C virus (HCV). Treatment options are improving and may
enhance prevention; however access for PWID may be poor. The
availability in the literature of information on seven main topic areas
(incidence, chronicity, genotypes, HIV co-infection, diagnosis and
treatment uptake, and burden of disease) to guide HCV treatment and
prevention scale-up for PWID in the 27 countries of the European Union
is systematically reviewed.
Methods and Findings: We searched MEDLINE, EMBASE and Cochrane Library
for publications between 1 January 2000 and 31 December 2012, with a
search strategy of general keywords regarding viral hepatitis, substance
abuse and geographic scope, as well as topic-specific keywords.
Additional articles were found through structured email consultations
with a large European expert network. Data availability was highly
variable and important limitations existed in comparability and
representativeness. Nine of 27 countries had data on HCV incidence among
PWID, which was often high (2.7-66/100 person-years, median 13,
Interquartile range (IQR) 8.7-28). Most common HCV genotypes were G1 and
G3; however, G4 may be increasing, while the proportion of traditionally
‘difficult to treat’ genotypes (G1+G4) showed large variation (median
53,IQR 43-62). Twelve countries reported on HCV chronicity (median 72,
IQR 64-81) and 22 on HIV prevalence in HCV-infected PWID (median 3.9%,
IQR 0.2-28). Undiagnosed infection, assessed in five countries, was high
(median 49%, IQR 38-64), while of those diagnosed, the proportion
entering treatment was low (median 9.5%, IQR 3.5-15). Burden of
disease, where assessed, was high and will rise in the next decade.
Conclusion: Key data on HCV epidemiology, care and disease burden among
PWID in Europe are sparse but suggest many undiagnosed infections and
poor treatment uptake. Stronger efforts are needed to improve data
availability to guide an increase in HCV treatment among PWID
Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-term Care Facilities: Data From the GeroCovid Vax Study
Objective: Type 2 diabetes may affect the humoral immune response after vaccination, but data concerning coronavirus disease 19 (COVID-19) vaccines are scarce. We evaluated the impact of diabetes on antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in older residents of long-term care facilities (LTCFs) and tested for differences according to antidiabetic treatment. Research design and methods: For this analysis, 555 older residents of LTCFs participating in the GeroCovid Vax study were included. SARS-CoV-2 trimeric S immunoglobulin G (anti-S IgG) concentrations using chemiluminescent assays were tested before the first dose and after 2 and 6 months. The impact of diabetes on anti-S IgG levels was evaluated using linear mixed models, which included the interaction between time and presence of diabetes. A second model also considered diabetes treatment: no insulin therapy (including dietary only or use of oral antidiabetic agents) and insulin therapy (alone or in combination with oral antidiabetic agents). Results: The mean age of the sample was 82.1 years, 68.1% were women, and 25.2% had diabetes. In linear mixed models, presence of diabetes was associated with lower anti-S IgG levels at 2 (β = -0.20; 95% CI -0.34, -0.06) and 6 months (β = -0.22; 95% CI -0.37, -0.07) after the first vaccine dose. Compared with those without diabetes, residents with diabetes not using insulin had lower IgG levels at 2- and 6-month assessments (β = -0.24; 95% CI -0.43, -0.05 and β = -0.30; 95% CI -0.50, -0.10, respectively), whereas no differences were observed for those using insulin. Conclusions: Older residents of LTCFs with diabetes tended to have weaker antibody response to COVID-19 vaccination. Insulin treatment might buffer this effect and establish humoral immunity similar to that in individuals without diabetes